Randomized trial of PPI-amoxicillin-clarithromycin and PPI-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy

Randomized trial of PPI-amoxicillin-clarithromycin and PPI-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy - Randomized trial of clarithromycin and metronidazole as first-line Helicobacter pylori eradication therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010229

Enrollment

120

Registered

2013-03-13

Start date

2013-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori associated gastritis

Interventions

The 7-day triple regimen composed of rabeprazole (10 mg, b.d.), clarithromycin (400 mg, b.d.), and amoxicillin (750 mg, b.d.), is administered. The 7-day triple regimen composed of rabeprazole (10 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients have H. pylori gastritis without peptic ulcer disease and no history of antibacterial therapy for eradication.

Exclusion criteria

Exclusion criteria: (1) age <20 years; (2) presence of clinically significant underlying disease (hepatic or renal disease, diabetes mellitus); (3) history of gastric surgery; (4) allergy to any of the drugs used in the study.

Design outcomes

Primary

Measure	Time frame
Eradication rate	—

Secondary

Measure	Time frame
Adverse effect	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026